ESElif Sen

Elif Sen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elif Sen has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenging diagnosis of central nervous system tuberculosis with joint involvement

    by Ahmet Melih Şahi̇n, Elif Şen, Zehra Akkaya, Turan Acican

  • Open Access

    Validation Study of Rome Criteria for Assessing COPD Exacerbation Severity and Predicting Clinical Outcomes: Turkish Thoracic Society COPD Assembly

    by Ayse Baha, Caner Baysan, Sibel Nayci, Eylem Ozgur, Tugce Karamustafalioglu, Elif Sen, Elif Selcuk, Gozde Mit, Aylin Alpaydin, Burcu Ozturk, et al.

    Objective: The Rome classification was introduced to assess the severity of acute exacerbation (AE) of chronic obstructive pulmonary disease (COPD) based on easily measurable variables. However, its validation for global use has not yet reached a sufficient level. This study aims to evaluate the validity of the Rome criteria in determining the severity and prognosis of COPD AE in Turkey. Methods: This multicenter study, conducted for the first time in Turkey and for the fourth time worldwide, included 750 patients diagnosed with AE-COPD who presented to emergency departments and outpatient clinics. According to the Rome criteria, patients were classified into three groups: mild, moderate, and severe AE-COPD. Results: The study included 99 (13.2%) patients in the mild, 479 (63.9%) in the moderate, and 172 (22.9%) in the severe group. Emergency visits, hospitalizations, and ICU admissions in the past year were more frequent in the moderate and severe groups (p < 0.001 for all comparisons). Regarding outcomes of emergency or outpatient visits, most mild exacerbation cases were discharged (p < 0.001), while most moderate and severe exacerbations required hospitalization (p < 0.001). Compared to the moderate group, the severe exacerbation group had a higher risk of ICU admission (p < 0.001), NIV (p < 0.001), IMV (p < 0.001), in-hospital mortality (p < 0.001), and 30-day mortality (p = 0.015). No significant differences were found in 90-day mortality or 30 and 90-day readmission rates (p = 0.258, p = 0.712, p = 0.681, respectively). Survival analysis revealed no significant difference between the moderate and severe groups (p = 0.764). Conclusion: The findings suggest that the Rome criteria can be successfully used to assess exacerbation severity in AE-COPD patients presenting to secondary and tertiary care hospitals in Turkey.


  • Open Access

    Patients with chronic obstructive pulmonary disease and the use of complementary and alternative medicine: The role of health literacy in Türkiye

    by Mustafa Ersözlü, Elif Akıncı Aydınlı, Elif Selçuk, Elif Şen

    Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous and chronic condition characterized by irreversible airflow obstruction. Health literacy may influence the use of complementary and alternative medicine (CAM). This study aims to investigate the role of health literacy in the use of CAM among COPD patients. Methods: This cross-sectional study was conducted at Ankara University School of Medicine, Department of Chest Diseases, involving patients with COPD between August 2024 and June 2025. Clinical COPD Questionnaire (CCQ) and Health Literacy Scale-Short Form (HLS-SF) were used to assess disease severity and health literacy, respectively. Results: Among 190 patients, inadequate and limited health literacy was more common among CAM users compared to non-users (n = 54/89, 61% vs n = 37/101, 37%, respectively, p = 0.007). CAM users were also more likely to have insufficient social support (n = 24/89, 25%, p = 0.047), cough (n = 79/89, 89%, p = 0.049), history of ICU admission (n = 19/89, 21%, p = 0.02), use of long-term oxygen therapy and noninvasive ventilation (n = 50/89, 56% p = p = p = p = 0.018; OR: 6.78, 95% CI: 1.63-28.0, p = 0.008, respectively), as well as GOLD E classification (OR: 2.71, 95% CI: 1.14-6.45, p = 0.024) and insufficient social support (OR: 2.56, 95% CI: 1.00-6.50, p = 0.048) after adjusting for age, sex, education, and comorbidities. Discussion: This study revealed the association between COPD symptom severity and frequent exacerbation, insufficient social support, along with lower health literacy and the use of CAM.


  • Open Access

    Asthma-chronic obstructive pulmonary disease overlap: Results from a national-multicenter study

    by Gülfem Elif Çeli̇k, Ömür Aydin, Elif Şen, Tunçalp Demi̇r, Bilun Gemi̇cİoĞlu, Esen Kiyan, Dilşad MUNGAN, İpEk Kivilcim Oğuzülgen, Mehmet Polatli, Özlem Göksel, et al.

    Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have a greater disease burden than those with COPD or asthma alone. In this study, it was aimed to determine the prevalence, risk factors, and clinical features of ACO because there are limited national data in Türkiye. The study was conducted in a cross-sectional design in nine tertiary-care hospitals. The patients followed with a diagnosis of asthma or COPD for at least one year were enrolled in the study. The frequency of ACO and the characteristics of the patients were evaluated in the asthma and COPD groups. The study included 408 subjects (F/M= 205/203, mean age= 56.24 ± 11.85 years). The overall prevalence of ACO in both groups was 20.8% (n= 85). The frequency was higher in the COPD group than in the asthma group (n= 55; 33.3% vs. n= 22; 9.8%), respectively (p= 0.001). Patients with ACO had similarities to patients with COPD in terms of advanced age, sex, smoking, exposure to biomass during childhood, being born in rural areas, and radiologic features. Characteristics such as a history of childhood asthma and allergic rhinitis, presence of chronic sinusitis, NSAID hypersensitivity, atopy, and high eosinophil counts were similar to those of patients with asthma (p<0.001). The annual decline in FEV1 was more prominent in the ACO group (mean= -250 mL) than in the asthma (mean change= -60 mL) and COPD (mean change= -230 mL) groups (p= 0.003). This study showed that ACO was common among patients with asthma and COPD in tertiary care clinics in our country. ACO should be considered in patients with asthma and COPD who exhibit the abovementioned symptoms.


  • Open Access

    Reliability of comorbidity indices as predictive indicators for frequent severe chronic obstructive pulmonary disease exacerbations

    by Deniz Doğan Mülazi̇mOğlu, Bilge Bi̇lGi̇n, Sümeyye Ayöz, Fatma Arslan, Elif Şen

    The relationship between comorbidities and chronic obstructive pulmonary disease (COPD) is two-sided. As the number of comorbidities increases, frequency of acute exacerbations of COPD (AECOPD) consequently increases. Comorbidity indices can be used to evaluate comorbidities while managing COPD patients. We aimed to compare comorbidity indices such as the Charlson comorbidity index (CCI), comorbidities in COPD index (COMCOLD) and COPD specific comorbidity test (COTE) regarding exacerbation frequency. Participants hospitalized for AECOPD were included in this bidirectional case-control study. Exacerbation severity, frequency, further exacerbations over a one-year follow-up period and CCI, COMCOLD, and COTE scores were recorded. High and low comorbidity groups were compared regarding AECOPD frequency, severity, and further exacerbations. Ninety-two patients were enrolled. The frequency of AECOPD was significantly higher in high-comorbidity groups (p= 0.026 for CCI; 0.015 for COTE; 0.012 for COMCOLD) than that in low-comorbidity groups. Severe AECOPD was significantly higher in all high-comorbidity groups according to the indices. Median number of exacerbations during the one-year follow-up period was significantly higher in the high-comorbidity groups defined by CCI [0 (0-4) vs. 1 (0-4), p<0.001 and COMCOLD 0 (0-4) vs. 1 (0-3), p= 0.007]. Comorbidities are among the most important risk factors for AECOPD. Managing comorbidities begins with their identification, followed by appropriate interventions. Therefore, using at least one comorbidity index during assessment ensures that comorbidities are not overlooked during diagnostic and therapeutic processes. CCI, COTE, and COMCOLD comorbidity indices can be used in predicting COPD exacerbations.


  • The effect of health-related quality of life and physical activity on time to first exacerbation in chronic obstructive pulmonary disease patients

    by Gökçen Arkan Demiral, Elif Şen

    It is known that there is a relationship between severe exacerbations of chronic obstructive pulmonary disease(COPD) requiring hospitalization with loss of forced expiratory volume in one second (FEV1), impaired quality of life, and increased mortality. The aim of this study was to investigate factors [health-related quality of life with COPD Assessment Test (CAT), physical activity, FEV1, PaO2] affecting the time to first exacerbation (TTFE) after discharge in patients hospitalized with exacerbation. Seventy-five patients who were hospitalized due to COPD acute exacerbation were included in the study and were prospectively monitored. First exacerbation after discharge was recorded. During the first three days of hospitalization, patients were fitted with a pedometer on any of these days; 24-hour step counts were recorded and CAT was administered through face-to-face interviews. Data on age, sex, PaO2, FEV1, and comorbidities were recorded. The median value of the CAT scores of the participants were taken as the cut-off point. High scores were considered as an indicator of poor quality of life. Cox regression models were created for multivariate analyses and hazard ratios (HR) with 95% confidence interval (95% CI) provided. There was a statistically significant relationship between the TTFE and CAT score (p= 0.001), FEV1 (pred %) (p= 0.02) and PaO2 (p= 0.02). No statistically significant relationship was found between TTFE and the number of steps used as an indicator of physical activity (p= 0.3). In multivariate analysis, age and sex adjusted CAT and PaO2 significantly affected the TTFE (HR= 2.06 CI 95%= 1.17-3.65 and HR= 5.50 CI 95%= 2.09-14.49, respectively) while adjusted FEV1 (pred %) was not significantly affected the TTFE (HR= 1.54 CI 95%= 0.88-2.70). The results of this study suggest that using CAT may be an easy-to-apply and practical tool to help identify patients with an increased risk of exacerbation. No significant correlation was found with the daily number of steps, which is an easily measurable indicator of physical activity.


  • Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer

    by Mine Araz, Cigdem Soydal, Elgin Özkan, Elif Sen, Demet Nak, Ozlem N. Kucuk, Ugur Gönüllü, K. Metin Kir

    Article: Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer - The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 Jul 01 - Minerva Medica - Journals


  • Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus

    by Mohamed S. Al-Moamary, Nurdan Köktūrk, Majdy M. Idrees, Elif Şen, George Juvelekian, Wajdy Abi Saleh, Zaid Zoumot, Naser Behbehani, Ashraf Hatem, Hosam H. Masoud, et al.


  • Open Access

    2021 Guideline for the Management of COPD Exacerbations

    by Nurettin Özgür Doğan, Yelda Varol, Nurdan Köktürk, Ersin Aksay, Aylin Özgen Alpaydın, Şeref Kerem Çorbacıoğlu, Gökhan Aksel, Ayşe Baha, Haldun Akoğlu, Sevilay Karahan, et al.

    Chronic obstructive pulmonary disease (COPD) is an important public health problem that manifests with exacerbations and causes serious mortality and morbidity in both developed and developing countries. COPD exacerbations usually present to emergency departments, where these patients are diagnosed and treated. Therefore, the Emergency Medicine Association of Turkey and the Turkish Thoracic Society jointly wanted to implement a guideline that evaluates the management of COPD exacerbations according to the current literature and provides evidence-based recommendations. In the management of COPD exacerbations, we aim to support the decision-making process of clinicians dealing with these patients in the emergency setting.


  • Does the 2017 revision improve the ability of GOLD to predict risk of future moderate and severe exacerbation?

    by Serhat Erol, Elif Sen, Yagmur Gizem Kilic, Ahmed Yousif, Oznur Akkoca Yildiz, Turan Acican, Sevgi Saryal

    Introduction: In 2017 update, GOLD separated spirometry from ABCD classification.Objectives: The aim was to investigate the predictive reliability of GOLD 2017 grading system in terms of future moderate and severe exacerbations.Methods: COPD patients were classified into A to D groups according to GOLD 2011 and 2017. Patients who were assigned to C/D groups according to GOLD 2011 were divided into subgroups C 1/D1, C2/D2, C3/D3 according to FEV1% of predicted and exacerbation history. C1/D1 patients defined as FEV1 < 50% predicted and without ≥2 exacerbations or hospitalization in the last year.Results: A total of 225 patients were enrolled. Among them, 25.8% were in groups C1/D1 according to GOLD 2011. These patients shifted to A/B according to GOLD 2017. C1/D1 patients had a significantly higher risk of future moderate and severe exacerbation compared to A/B (P = 0.018). The risk of future moderate and severe exacerbation was significantly higher in patients with a FEV1 < 50% (P = 0.018).The risk of future moderate and severe exacerbation was higher in GOLD 2017 groups A and B compared to GOLD 2011 groups A and B.Conclusion: Low FEV1 was an important risk factor for future exacerbations. Downstaging of C1/D1 patients caused heterogeneity in A/B with including patients with low and high risk of future exacerbation. This resulted in a low discriminative power of GOLD 2017 regarding the risk of future exacerbation in groups A and B. This may cause underestimation of disease severity and inadequate treatment especially in A/B patients with low FEV1.